



Sociedade
Brasileira de
Infectologia

Contents lists available at ScienceDirect

Brazilian Journal of Infectious Diseases

journal homepage: www.elsevier.com/locate/bjid



Original Article

Activity of ceftolozane/tazobactam and comparators against gram-negative bacilli: Results from the Study for Monitoring Antimicrobial Resistance Trends (SMART – Brazil), 2018–2021

Amanda Azevedo Bittencourt^{a,*}, Vinicius Lima Faustino^a, Paula de Mendonça Batista^a,
Lays Paulino Leonel^b, Marina Della Negra de Paula^a, Thales José Polis^a

^a Global Medical & Scientific Affairs (GMSA), MSD Brazil, São Paulo, SP, Brazil

^b Real World Evidence, IQVIA Brazil, São Paulo, SP, Brazil



ARTICLE INFO

Keywords:

Antibiotics
Bacterial infections
Gram-negative bacilli (GNB)
Surveillance

ABSTRACT

Increased spread of antimicrobial resistance by Gram-Negative Bacilli (GNB) poses a global challenge, with exacerbated burden post-pandemic. The aim of this study was to investigate the *in vitro* activity of ceftolozane/tazobactam and its comparators against the frequently identified GNB isolated from patients admitted to Brazilian medical sites between the year 2018–2019 and 2020–2021. The impact of pandemic on antimicrobial resistance and presence of β -lactamase genes were also evaluated. Antimicrobial susceptibility testing and molecular characterization of β -lactamase encoding genes using Polymerase Chain Reaction (PCR) and DNA sequencing were carried out from GNB isolated mostly from intra-abdominal, respiratory, and urinary tract infections and interpreted following BrCAST/EUCAST guidelines. A total of 3994 GNB isolates were evaluated which mostly included *E. coli*, *K. pneumoniae* and *P. aeruginosa*. Ceftolozane/tazobactam remained highly active against *E. coli* isolates during both 2018–2019 (96.0 %) and 2020–2021 (98.5 %). Among *K. pneumoniae*, ceftolozane/tazobactam (47.6 % and 43.0 % susceptible during 2018–2019 and 2020–2021, respectively) showed poor activity due to *bla*_{KPC-2}. Colistin and ceftolozane/tazobactam were the most active β -lactam agents tested against *P. aeruginosa* in 2018–2019 (99.3 % and 88.8 %) and 2020–2021 (100 % and 92.8 %), including ceftazidime and meropenem resistant isolates. β -lactamase encoding gene characterization was carried out and both carbapenemases and Extended-Spectrum β -Lactamase (ESBL) producers were found in *E. coli*, *K. pneumoniae* and *P. aeruginosa* isolates. Ceftolozane/tazobactam documented remarkable *in vitro* activity against *E. coli* and *P. aeruginosa* isolates in Brazil, both pre- and post-pandemic periods and could constitute an effective therapeutic option for the treatment of urinary tract infections, intra-abdominal infections, and respiratory tract infections.

Introduction

Antimicrobial Resistance (AMR) is one of the leading global threats. It occurs when changes in bacteria, viruses, fungi and parasites make existing antibiotics ineffective or less effective, increasing the burden on society. The World Health Organization (WHO) emphasizes the need to have a global coordinated action to prevent further spread of AMR.¹ According to the 2016 AMR review, it was projected that around 10 million individuals might die annually due to AMR by the year 2050.²

The rise in bacterial resistance has led to a significant threat posed by Gram-Negative Bacilli (GNB) with Multidrug Resistance (MDR). This poses a challenge to the medical and scientific community as there are

limited treatment options available to control infections caused by bacteria such as *K. pneumoniae*, *P. aeruginosa* and *E. coli*.³ As a result of the increased prevalence of Extended-Spectrum β -Lactamase (ESBL) production among GNB, carbapenem antibiotics have been utilized extensively.⁴ In low middle income countries, including Brazil, resistance to carbapenems has developed due to their increased use.⁴⁻⁶

In Brazil, serious hospital-acquired infections have been linked to GNB exhibiting resistance to various antimicrobial agents.⁷ The pandemic caused by the Coronavirus Disease (COVID-19) has significantly intensified the challenge of AMR. This escalation can be attributed to the surge in infection rates, which has led to an increase in hospital admissions and the use of invasive medical devices.

* Corresponding author.

E-mail address: amanda.bittencourt@merck.com (A.A. Bittencourt).

<https://doi.org/10.1016/j.bjid.2024.104497>

Received 12 August 2024; Accepted 2 December 2024

Available online 12 December 2024

1413-8670/© 2025 Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA and The Author(s). Published by Elsevier Ltd. Published by Elsevier España, S.L.U. on behalf of British Society of Infectious Diseases. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Consequently, this has resulted in prolonged hospital stays and a higher mortality rate.⁸⁻¹⁰ Furthermore, there has been a noticeable rise in carbapenem resistance during the pandemic period.^{4,11,12}

Health authorities in many countries have recommended the use of alternative antibiotics and different combinations of medications to reduce the further spread of resistance.¹³ Novel β -Lactam/ β -Lactamase Inhibitors (BL/BLIs) including ceftolozane/tazobactam, ceftazidime/avibactam, and imipenem/relebactam have emerged as salvage therapies for infections due to pathogens that are resistant to most antibiotics.^{14,15}

Ceftolozane/tazobactam is comparatively a newer antimicrobial that was approved by the United States Food and Drug Administration in 2014 for the treatment of complicated Intra-Abdominal Infections (cIAI) and complicated Urinary Tract Infections (cUTI), including pyelonephritis at a dosage of 1.5 g, three times a day and hospital-acquired/ventilator-associated bacterial pneumonia (HABP/VABP) at a dosage of 3 g every 8 h.¹⁶⁻¹⁸ It was approved in Brazil by the national health regulatory agency in Portuguese *Agência Nacional de Vigilância Sanitária* (ANVISA) for cUTI and cIAI in 2018 and for HABP/VABP in 2020.¹⁹⁻²¹ The drug combines the new cephalosporin ceftolozane having higher affinity for penicillin-binding proteins compared with other β -lactam agents, high stability against amp-C type β -lactamases, with tazobactam providing increased activity against organisms producing ESBL.¹⁷

Surveillance data at the national level is necessary, along with the establishment of standardized dosage regimens for the utilization of ceftolozane/tazobactam. This is particularly important for patients suffering from severe respiratory infection and hospital-acquired or ventilator-associated bacterial pneumonia (HABP/VABP) who are critically ill.^{14,20-22}

The Study for Monitoring Antimicrobial Resistance Trends (SMART) program has generated data on the frequency of antimicrobial susceptibility of GNB associated with Urinary Tract Infections (UTI), Intra-Abdominal Infections (IAI) and Respiratory Tract Infections (RTI), which helps to delineate the changes in the epidemiology of gram-negative infections over time.^{19,23}

The principal aim of this study was to determine the frequency of pathogens and *in vitro* activity of ceftolozane/tazobactam and its comparators against the frequently identified GNB isolated from patients admitted to medical study sites across Brazil between the years 2018–2019 and 2020–2021. The study was conducted in two time periods to assess the impact of COVID-19 on AMR.

Methods

Bacterial isolates

Non-duplicate GNB isolates were collected from ten study sites across six Brazilian cities: Belo Horizonte (one), Curitiba (one), Recife (one), Rio de Janeiro (two), Salvador (one) and São Paulo (four), from 2018–2021, as part of the SMART surveillance program.

GNB were identified at the species level at the respective participant medical sites and shipped to a central microbiology laboratory (International Health Management Associates, IHMA, Schaumburg, IL, USA), where confirmation of bacterial species, antimicrobial susceptibility testing, and molecular characterization of β -lactamase encoding genes were carried out. Bacterial identification at the species level was confirmed for all isolates using MALDI-TOF spectrometry (Bruker Daltonics, Billerica, MA, USA).

Susceptibility testing

Antimicrobial susceptibility testing for amikacin, aztreonam, cefepime, cefotaxime, ceftazidime, ceftolozane/tazobactam, ceftriaxone, ciprofloxacin, colistin, ertapenem, imipenem, meropenem, and piperacillin/tazobactam was determined by the Clinical & Laboratory Standards Institute (CLSI) reference broth microdilution method²⁴ using broth microdilution panels prepared at IHMA and were interpreted

following BrCAST/EUCAST guidelines.^{25,26} Quality control (QC) of broth microdilution panels followed CLSI guidelines using the ATCC strains: *E. coli* ATCC 25,922, *P. aeruginosa* ATCC 27,853, *K. pneumoniae* ATCC 700,603 and *K. pneumoniae* BAA 2814, with corresponding QC values within the specified acceptable ranges. *E. coli* and *K. pneumoniae* isolates with Minimal Inhibitory Concentrations (MIC) ≥ 2 $\mu\text{g/mL}$ for ceftazidime, ceftriaxone, or aztreonam were screened as “ESBL phenotype”. Enterobacterales with MIC ≥ 4 $\mu\text{g/mL}$ for imipenem and/or meropenem were defined as carbapenem resistant. *P. aeruginosa* isolates having MICs > 8 $\mu\text{g/mL}$ and > 2 $\mu\text{g/mL}$ were classified as not susceptible to ceftazidime and meropenem, respectively.

Molecular characterization of β -lactamase encoding genes

Isolates meeting the following phenotypic criteria were screened for β -lactamase genes: non-Morganellaceae Enterobacterales (NME) isolates (excluding *Serratia* spp.) testing with imipenem or imipenem/relebactam MIC values of ≥ 2 mg/L; *P. aeruginosa* isolates testing with imipenem or imipenem/relebactam MIC values of ≥ 4 mg/L; NME and *Serratia* spp. isolates testing with ertapenem MIC values of ≥ 1 mg/L collected in 2018 only; isolates of *Serratia* spp. testing with imipenem MIC values of ≥ 4 mg/L collected in 2018; and Enterobacterales and *P. aeruginosa* isolates testing with ceftolozane/tazobactam MIC values of ≥ 4 mg/L and ≥ 8 mg/L, respectively. Previously published multiplex PCR assays were used to screen for the following β -lactamase genes (bla): ESBLs (CTX-M, GES, PER, SHV, TEM, VEB); acquired AmpC β -lactamases (ACC, ACT, CMY, DHA, FOX, MIR, MOX); serine carbapenemases (GES, KPC, OXA-48-like [Enterobacterales], OXA-24-like [*P. aeruginosa*]); and Metallo- β -Lactamases (MBLs) (GIM, IMP, NDM, SPM, VIM).²³ All detected acquired β -lactamase genes were re-amplified using gene-flanking primers and sequenced in full (Sanger) with the exception that limited sequencing was performed on bla_{TEM} and bla_{SHV} to identify genes encoding bla_{TEM}-type and bla_{SHV}-type enzymes containing amino acid substitutions common to ESBLs (SHV A146 V, G238S, G238A, E240 K; TEM E104 K, R164S, R164C, R164H, G238S). Limited sequencing was also performed on bla_{CTX-M} to identify the presence of the D240G substitution in the deduced amino acid sequence associated with increased ceftazidime hydrolysis. For *P. aeruginosa* isolates, collected in 2020 and 2021, characterization was performed using short-read whole-genome sequencing (Illumina HiSeq 2 \times 150 bp reads) to a targeted coverage depth of 100 \times ²⁵ and analyzed using the CLC Genomics Workbench (Qiagen). The Resfinder database was used to detect β -lactamase genes in whole-genome sequencing assemblies.²⁶ Per SMART protocol for Enterobacterales isolates collected in 2021, a representative sample of approximately 95 % of isolates meeting the criteria for molecular characterization were characterized. Per SMART protocol for *P. aeruginosa* isolates collected in 2020 and 2021, a representative sample of approximately 75 % of isolates meeting the criteria for molecular characterization were characterized.

Data analysis and availability

All data analyses were performed in Excel (Microsoft, Redmond, WA). Data are available on request.

Results

A total of 3994 GNB isolates were collected from all the study sites between 2018–2021 [2018, $n = 754$ (18.9 %); 2019, $n = 982$ (24.6 %); 2020, $n = 951$ (23.8 %); 2021, $n = 1307$ (32.7 %)]. More than half of the total isolates were recovered from male patients ($n = 2190$, 54.8 %) aged 50 and above ($n = 2861$, 71.6 %). The most frequent hospital ward was General Medicine ($n = 1433$, 35.9 %), followed by Intensive Care Units (ICUs) ($n = 1029$, 25.8 %). About one-fourth of the isolated species were *E. coli* ($n = 1003$, 25.1 %), while the other commonly isolated species included were *K. pneumoniae* ($n = 772$, 19.3 %) and *P. aeruginosa* ($n =$

693, 17.4 %) (Fig. 1).

The distribution of the five most frequent GNB species according to the site of infection is depicted in Fig. 2. Most of the isolated pathogens were obtained from RTI ($n = 1925$, 48.2 %) followed by UTI ($n = 1221$, 30.6 %) and IAI ($n = 848$, 21.2 %). The most commonly isolated pathogens in RTI were *P. aeruginosa* ($n = 491$, 25.5 %), *K. pneumoniae* ($n = 360$, 18.7 %) and *A. baumannii* ($n = 268$, 13.9 %). The most frequent species isolated in UTI were *E. coli* ($n = 584$, 47.8 %), followed by *K. pneumoniae* ($n = 255$, 20.9 %) and *P. aeruginosa* ($n = 102$, 8.3 %). For IAI, the most frequent isolated species were *E. coli* ($n = 323$, 38.1 %), *K. pneumoniae* ($n = 157$, 18.5 %) and *P. aeruginosa* ($n = 100$, 11.8 %).

Antimicrobial susceptibility

Antimicrobial susceptibility profiles of the most frequent GNB causing infections are elaborated in Table 1. During the period 2018–2019, ceftazidime/avibactam ($\text{MIC}_{50/90}$, $\leq 0.12/0.25$ $\mu\text{g/mL}$, $n = 532$, 100 % susceptible) and imipenem/relebactam ($\text{MIC}_{50/90}$, $\leq 0.12/ \leq 0.25$ $\mu\text{g/mL}$, $n = 532$, 100 % susceptible), were the most active *in vitro* agents tested against the *E. coli* isolates, followed by meropenem ($\text{MIC}_{50/90}$, $\leq 0.12/ \leq 0.12$ $\mu\text{g/mL}$, $n = 530$, 99.6 % susceptible), colistin ($\text{MIC}_{50/90}$, $\leq 1/ \leq 1$ $\mu\text{g/mL}$, $n = 528$, 99.2 % susceptible), imipenem ($\text{MIC}_{50/90}$, $\leq 0.12/ \leq 0.25$ μg , $n = 524$, 98.5 % susceptible), and ertapenem ($\text{MIC}_{50/90}$, $\leq 0.12/ \leq 0.12$ μg , $n = 518$, 97.3 % susceptible).

Similar results were observed during the 2020–2021 period, with slightly lower susceptibility percentages for ceftazidime/avibactam ($\text{MIC}_{50/90}$, $\leq 0.12/0.25$ $\mu\text{g/mL}$, $n = 468$, 99.4 % susceptible), meropenem ($\text{MIC}_{50/90}$, $\leq 0.12/ \leq 0.12$ $\mu\text{g/mL}$, $n = 468$, 99.4 % susceptible) and imipenem/relebactam ($\text{MIC}_{50/90}$, $\leq 0.12/ \leq 0.25$ $\mu\text{g/mL}$, $n = 468$, 99.4 % susceptible) (Table 1).

In contrast, the lowest susceptibility rates in the period of 2018–2019 were observed for ciprofloxacin ($\text{MIC}_{50/90}$, $0.5/ > 2$ $\mu\text{g/mL}$, $n = 98$, 50.3 % susceptible), followed by ceftriaxone ($\text{MIC}_{50/90}$, $\leq 1/ > 8$ $\mu\text{g/mL}$, $n = 400$, 75.2 % susceptible), and aztreonam ($\text{MIC}_{50/90}$, $\leq 1/ > 8$ $\mu\text{g/mL}$, $n = 425$, 79.9 % susceptible). For the period 2020–2021, ciprofloxacin was not included in the panel of antimicrobials used for GNB infections, and ceftriaxone showed lowest susceptibility ($\text{MIC}_{50/90}$, $\leq 1/ > 8$ $\mu\text{g/mL}$, $n = 357$, 75.8 % susceptible).

Ceftazidime/avibactam ($\text{MIC}_{50/90}$, $\leq 0.12/0.25$ $\mu\text{g/mL}$, $n = 134$) and imipenem/relebactam ($\text{MIC}_{50/90}$, $\leq 0.12/0.25$ $\mu\text{g/mL}$, $n = 134$) remained highly active against *E. coli* isolates exhibiting the ESBL phenotype with a susceptibility of 100 % during 2018–2019 as shown in

Table 2. During 2020–2021 period, colistin ($\text{MIC}_{50/90}$, $\leq 1/ \leq 1$ $\mu\text{g/mL}$, $n = 113$, 99.1 % susceptible) exhibited higher susceptibility against *E. coli* isolates exhibiting the ESBL phenotype followed by ceftazidime/avibactam ($\text{MIC}_{50/90}$, $\leq 0.12/0.25$ $\mu\text{g/mL}$, $n = 111$, 97.4 % susceptible), imipenem/relebactam ($\text{MIC}_{50/90}$, $0.25/0.25$ $\mu\text{g/mL}$, $n = 111$, 97.4 % susceptible) and meropenem ($\text{MIC}_{50/90}$, $\leq 0.12/ \leq 0.12$ $\mu\text{g/mL}$, $n = 111$, 97.4 % susceptible).

During the period 2018–2019, among the *K. pneumoniae* evaluated in this study, the highest susceptibility rates were observed for ceftazidime/avibactam ($\text{MIC}_{50/90}$, $0.5/2$ $\mu\text{g/mL}$, $n = 307$, 96.2 % susceptible) and imipenem/relebactam ($\text{MIC}_{50/90}$, $0.25/1$ $\mu\text{g/mL}$, $n = 306$, 95.9 % susceptible). Ciprofloxacin, ceftriaxone and piperacillin/tazobactam showed poor *in vitro* activity against isolates of *K. pneumoniae* as displayed in Table 1. Similar results were observed during 2020–2021 period for highest susceptibility rates, with ceftazidime/avibactam ($\text{MIC}_{50/90}$, $0.5/4$ $\mu\text{g/mL}$, $n = 414$, 91.4 % susceptible) and imipenem/relebactam ($\text{MIC}_{50/90}$, $0.25/2$ $\mu\text{g/mL}$, $n = 411$, 90.7 % susceptible) (Table 1).

K. pneumoniae exhibiting an ESBL phenotype was highly susceptible to ceftazidime/avibactam ($\text{MIC}_{50/90}$, $0.25/2$ $\mu\text{g/mL}$, $n = 192$, 94.1 %) and imipenem/relebactam ($\text{MIC}_{50/90}$, $0.25/1$ $\mu\text{g/mL}$, $n = 191$, 93.6 %) during the period 2018–2019, as shown in Table 2. For the period 2020–2021, similarly highest susceptibility rates were observed for ceftazidime/avibactam ($\text{MIC}_{50/90}$, $1/ > 16$ $\mu\text{g/mL}$, $n = 285$, 88.0 %) and imipenem/relebactam ($\text{MIC}_{50/90}$, $0.25/8$ $\mu\text{g/mL}$, $n = 282$, 87.0 %).

Further, colistin ($\text{MIC}_{50/90}$, ≤ 1 $\mu\text{g/mL}$ for both) and ceftolozane/tazobactam ($\text{MIC}_{50/90}$, $0.5/8$ $\mu\text{g/mL}$) were the most active *in vitro* agents tested against the *P. aeruginosa* isolates with susceptibility of 99.3 % ($n = 286$) and 88.9 % ($n = 256$) respectively during the period 2018–2019. During the 2020–2021 period, colistin ($\text{MIC}_{50/90}$, 1 $\mu\text{g/mL}$ for both), ceftolozane/tazobactam ($\text{MIC}_{50/90}$, $0.5/4$ $\mu\text{g/mL}$) and ceftazidime/avibactam ($\text{MIC}_{50/90}$, $2/8$ $\mu\text{g/mL}$) were the most active agents against the *P. aeruginosa* isolates with susceptibility of 100 % ($n = 405$), 92.8 % ($n = 376$) and 90.4 % ($n = 366$) respectively (Table 1). Further for *P. aeruginosa* isolates non-susceptible to meropenem, colistin ($\text{MIC}_{50/90}$, $\leq 1/1$ $\mu\text{g/mL}$) had high susceptibility rate of 100 % in both the study periods. Additionally, ceftolozane/tazobactam emerged as the most potent beta-lactam agent, demonstrating a susceptibility rate of 73 % in the 2018–2019 period ($n = 100$) and 78 % in the 2020–2021 period ($n = 130$) (Table 2).




Fig. 1. Distribution of isolates according to the bacterial species collected from participating Brazilian medical centers of the SMART Program (Brazil, 2018–2021).




Fig. 2. Distribution of bacterial species according to the site of infection (SMART Program – Brazil 2018–2021).

Detection of beta-lactamase encoding genes

The distribution of β -lactamase encoding genes according to bacterial species is shown in Table 3. 250 *E. coli* were tested, of these 17 were carbapenemases producers and 18 were ESBL producers. The carbapenemase producing isolates showed predominance of bla_{KPC-2} ($n = 15$; 88.2 %). $bla_{CTX-M-1-240 G}$ ($n = 9$, 50 %) was found in the majority of ESBL producing isolates.

Among *K. pneumoniae*, 494 were tested which included carbapenemase ($n = 302$, 48.5 %) and ESBL ($n = 320$, 51.4 %) producers. Most of the isolates encoding carbapenemases were harboring bla_{KPC-2} ($n = 260$, 86.1 %) gene.

Among 353 of tested *P. aeruginosa*, 23 isolates had carbapenemases encoding genes and nine had ESBL encoding genes. bla_{SPM-1} ($n = 10$, 43.5 %) was most frequently detected in the carbapenemase group and $bla_{CTX-M-2}$ and $bla_{CTX-M-229}$ ($n = 4$, 44.4 % for both) in the ESBL group.

Discussion

Surveillance studies play a crucial role in addressing the worldwide dissemination of AMR. These studies aid in comprehending the extent of the problem, unraveling the mechanisms underlying resistance, and generating data to facilitate the development of novel agents or enhance

existing agents.^{27,28} Empirical regimens to treat GNB infections are based on the most prevalent pathogens causing infection and their antimicrobial susceptibility patterns. The WHO has also issued a public health warning and called nations to share AMR status through the implementation of the Global Antimicrobial Resistance Surveillance System (GLASS). In 2018, Brazil initiated its national antimicrobial surveillance program (BR-GLASS). However, considering the observed rise in resistance following the pandemic, it is imperative to encourage additional surveillance in Brazil, to gain greater comprehension of the present situation.^{29,30} In the current study, we assessed the AMR trends for two time periods, 2018–2019 and 2020–2021, to assess the impact of COVID-19 on the antimicrobial status.

In our study the most frequent GNB isolated from the RTI, UTI and IAI sites included *E. coli*, *K. pneumoniae* and *P. aeruginosa*. In the previous SMART study done in Brazil (2016–2017), ceftolozane/tazobactam had shown high antibacterial *in vitro* activity against *E. coli* with > 90 % susceptibility.⁷ Similar results were observed in the current extended study during both the time periods (96.0 % for 2018–2019 and 98.5 % for 2020–2021). Comparable susceptibility profiles have been documented in prior research conducted in Eastern and Western Europe, Portugal, the United States, Hong Kong, and South Korea.^{23,31–33} GNB isolates collected from ICU in 7 different Asian countries in another SMART study (2017–2019) showed ceftolozane/tazobactam having 86

Table 1
Antimicrobial susceptibility profile of the most frequent GNB causing infections in the Brazilian population.

GNB Antimicrobial Agents (N1, N2)	Broth Microdilution ($\mu\text{g/mL}$)				EUCAST			
	MIC ₅₀		MIC ₉₀		S+SIE (%)		R (%)	
	2018–2019	2020–2021	2018–2019	2020–2021	2018–2019	2020–2021	2018–2019	2020–2021
<i>E. coli</i>								
Amikacin (532, 471)	≤ 8	≤ 8	≤ 8	≤ 8	95.7 %	97.6 %	4.3 %	2.3 %
Aztreonam (532, 471)	≤ 1	≤ 1	> 8	> 8	79.8 %	82.5 %	20.1 %	17.4 %
Cefepime (532, 471)	≤ 1	≤ 1	> 16	16	81.0 %	84.7 %	18.9 %	15.2 %
Ceftazidime (532, 471)	≤ 1	≤ 1	16	8	81.9 %	86.0 %	18.0 %	14.0 %
Ceftazidime/avibactam (532, 471)	≤ 0.12	≤ 0.12	0.25	0.25	100.0 %	99.4 %	0.0 %	0.6 %
Ceftolozane/tazobactam (532, 471)	≤ 0.12	≤ 0.12	0.5	0.5	96.0 %	98.5 %	3.9 %	1.4 %
Ceftriaxone (532, 471)	≤ 1	≤ 1	> 8	> 8	75.1 %	75.8 %	24.8 %	24.2 %
Ciprofloxacin (195)	0.5	–	> 2	–	50.2 %	–	49.7 %	–
Colistin (532, 471)	≤ 1	≤ 1	≤ 1	≤ 1	99.2 %	99.8 %	0.7 %	0.2 %
Ertapenem (532, 471)	≤ 0.12	≤ 0.12	≤ 0.12	≤ 0.12	97.3 %	97.2 %	2.6 %	2.7 %
Imipenem (532, 471)	≤ 0.12	0.25	0.25	0.5	98.5 %	98.9 %	1.5 %	1.0 %
Imipenem/relebactam (532, 471)	≤ 0.12	0.25	0.25	0.25	100.0 %	99.4 %	0.0 %	0.6 %
Meropenem (532, 471)	≤ 0.12	≤ 0.12	≤ 0.12	≤ 0.12	99.6 %	99.4 %	0.3 %	0.6 %
Piperacillin/tazobactam (532, 471)	≤ 4	≤ 4	16	8	88.9 %	92.7 %	11.0 %	7.2 %
<i>K. pneumoniae</i>								
Amikacin (319, 453)	≤ 8	≤ 8	16	≤ 8	88.4 %	78.1 %	11.6 %	21.8 %
Aztreonam (319, 453)	> 8	> 8	> 16	> 8	39.8 %	31.3 %	60.1 %	68.6 %
Cefepime (319, 453)	> 16	> 16	> 16	> 16	42.0 %	32.6 %	57.9 %	67.3 %
Ceftazidime (319, 453)	> 16	> 16	> 16	> 16	40.1 %	32.6 %	59.8 %	67.3 %
Ceftazidime/avibactam (319, 453)	0.5	0.5	2	4	96.2 %	91.3 %	3.7 %	8.6 %
Ceftolozane/tazobactam (319, 453)	4	16	> 16	> 16	47.6 %	43.0 %	52.3 %	56.9 %
Ceftriaxone (319, 453)	> 8	> 4	> 8	> 8	36.6 %	28.7 %	63.3 %	71.3 %
Ciprofloxacin (123)	> 2	–	> 2	–	36.5 %	–	63.4 %	–
Colistin (319, 453)	≤ 1	≤ 1	> 4	> 4	88.0 %	82.3 %	11.9 %	17.6 %
Ertapenem (319, 453)	0.25	> 2	> 4	> 4	55.4 %	46.5 %	44.5 %	53.4 %
Imipenem (319, 453)	0.5	1	> 16	> 16	66.4 %	52.3 %	33.5 %	47.6 %
Imipenem/relebactam (319, 453)	0.25	0.25	1	2	95.9 %	90.7 %	4.0 %	9.2 %
Meropenem (319, 453)	≤ 0.12	1	> 16	> 16	72.1 %	59.1 %	27.9 %	40.8 %
Piperacillin/tazobactam (319, 453)	64	> 64	> 64	> 64	38.5 %	32.4 %	61.4 %	67.5 %
<i>P. aeruginosa</i>								
Amikacin (288, 405)	≤ 4	≤ 4	> 32	32	87.8 %	89.3 %	12.1 %	10.6 %
Aztreonam (288, 405)	8	8	> 16	> 16	78.4 %	79.7 %	21.5 %	20.2 %
Cefepime (288, 405)	4	4	32	32	71.8 %	79.0 %	28.1 %	20.9 %
Ceftazidime (288, 405)	4	4	> 32	> 32	70.8 %	79.2 %	29.1 %	20.7 %
Ceftazidime/avibactam (288, 405)	2	2	16	8	87.5 %	90.4 %	12.5 %	9.6 %
Ceftolozane/tazobactam (288, 405)	0.5	0.5	8	4	88.9 %	92.8 %	11.1 %	7.1 %
Ciprofloxacin (136,0)	≤ 0.25	–	> 2	–	61.7 %	–	38.2 %	–
Colistin (288, 405)	≤ 1	1	≤ 1	1	99.3 %	100.0 %	0.6 %	0.0 %
Imipenem (288, 405)	2	4	32	32	63.8 %	66.9 %	36.1 %	33.0 %
Imipenem/relebactam (288, 405)	1	1	4	4	80.9 %	81.2 %	19.1 %	18.7 %
Meropenem (288, 405)	1	1	32	16	76.3 %	82.7 %	23.6 %	17.2 %
Piperacillin/tazobactam (288, 405)	8	8	> 64	> 64	65.2 %	73.5 %	34.7 %	26.4 %

GNB, Gram-Negative Bacilli; N1, Number of isolates tested during 2018–2019; N2, Number of isolates tested during 2020–2021; EUCAST, European Committee on Antimicrobial Susceptibility Testing; SI +SIE, Susceptible + Susceptible Increased exposure.

% susceptibility for *E. coli*.²³ The STEP multicenter study in Portugal also reported high susceptibility for *E. coli* (99.4 %) among ICU patients.³¹ Similar results were observed in a study (2012–2018) including various European countries with ceftolozane/tazobactam demonstrating potent *in vitro* activity against *E. coli* from both Western Europe (99 %) and Eastern Europe (96 %).³³ Despite the lack of clarity regarding the precise role of ceftolozane/tazobactam against ESBL-producing organisms, it has demonstrated promising outcomes in the treatment of ESBL-producing *Enterobacteriales*, including severe infections.^{16,34–36} In a multicenter, retrospective study conducted in Italy, favorable clinical outcomes were observed in 84 % of patients with severe infections caused by ESBL-producing *Enterobacteriales* who were treated with ceftolozane/tazobactam.³⁵ A pooled analysis of Phase 3 clinical trials reported around 72 % of ESBL-producing *Enterobacteriales* (88 % for *E. coli* and 36 % for *K. pneumoniae*) susceptible to ceftolozane/tazobactam.³⁶ Many of the global surveillance studies also demonstrated high susceptibility of ESBL producing *Enterobacteriales* to ceftolozane/tazobactam for critically-ill and immunocompromised patients.^{34,37} Consistent with these, in our study also, the combination was susceptible for ESBL-producing *E. coli* in both study time periods, 84.3 % during 2018–2019 and 93.8 % during 2020–2021, similar to previous SMART

study in Brazil, emphasizing it as an alternative treatment therapy for ESBL-producing organisms.¹⁹

Significant rates of ciprofloxacin resistance (> 50 %) were detected in *E. coli* and *K. pneumoniae* isolates during the 2018–2019 study period, validated by the findings of SMART Brazil – 2016–2018 that disfavor the empirical prescribing of this fluoroquinolone in our specific setting.¹⁹

Among the three groups studied, *K. pneumoniae* showed higher resistance to many treatment drugs. The resistance rates to ceftolozane/tazobactam, ceftriaxone and piperacillin/tazobactam were high (> 50 %) for both time periods studied. Similar resistance rates for ceftolozane/tazobactam were observed in some previous studies in Saudi Arabia (51.6 %), Poland (70 %) and Asian-Pacific (APAC) countries (43.4 % for ESBL non-CRE isolates).^{38–40} However, it is important to highlight that this present study had a limitation and was unable to identify if any of the ESBLs were also CRE isolates, which may justify the susceptibility of these isolates to those B-lactam.

There have been increased occurrences of carbapenem resistance in strains of *P. aeruginosa*, reported as over 60 % in Brazilian hospitals, causing high mortality.^{41,42} Mutations affecting the permeability of the microorganisms to carbapenems, and further overexpression of efflux

Table 2
Susceptibility rates to distinct antimicrobial agents of the frequent pathogens according to the phenotype of resistance in Brazil.

GNB Antimicrobial Agents (N1, N2)	Broth Microdilution ($\mu\text{g/mL}$)				EUCAST			
	MIC ₅₀		MIC ₉₀		S+SIE (%)		R (%)	
	2018–2019	2020–2021	2018–2019	2020–2021	2018–2019	2020–2021	2018–2019	2020–2021
ESBL - producing <i>E. coli</i>								
Amikacin (134, 114)	≤8	≤8	16	≤8	88.0 %	94.7 %	11.9 %	5.2 %
Aztreonam (134, 114)	>8	8	>16	>8	20.1 %	28.0 %	79.8 %	71.9 %
Cefepime (134, 114)	16	8	>16	>16	24.6 %	36.8 %	75.5 %	63.1 %
Ceftazidime (134, 114)	8	8	>16	>16	28.3 %	42.1 %	71.6 %	57.8 %
Ceftazidime/avibactam (134, 114)	≤0.12	≤0.12	0.25	0.25	100.0 %	97.4 %	0.0 %	2.6 %
Ceftolozane/tazobactam (134, 114)	0.5	0.25	8	1	84.3 %	93.8 %	15.6 %	6.1 %
Ceftriaxone (134, 114)	>8	>8	>8	>8	1.4 %	0.0 %	98.5 %	100.0 %
Ciprofloxacin (52, 0)	>2	–	>2	–	15.3 %	–	84.6 %	–
Colistin (134, 114)	≤1	≤1	≤1	≤1	97.7 %	99.1 %	2.2 %	0.8 %
Ertapenem (134, 114)	≤0.12	≤0.12	2	0.25	89.5 %	91.2 %	10.4 %	8.7 %
Imipenem (134, 114)	0.25	0.25	1	1	94.0 %	95.6 %	5.9 %	4.3 %
Imipenem/relebactam (134, 114)	≤0.12	0.25	0.25	0.25	100.0 %	97.4 %	0.0 %	2.6 %
Meropenem (134, 114)	≤0.12	≤0.12	0.5	≤0.12	98.5 %	97.4 %	1.4 %	2.6 %
Piperacillin/tazobactam (134, 114)	4	≤4	>64	32	64.9 %	80.7 %	35.0 %	19.3 %
ESBL - producing <i>K. pneumoniae</i>								
Amikacin (204, 324)	≤ 8	≤ 8	32	>32	81.8 %	69.7 %	18.1 %	30.2 %
Aztreonam (204, 324)	>8	>8	>16	>8	5.9 %	4.0 %	94.1 %	95.9 %
Cefepime (204, 324)	>16	>16	>16	>16	9.8 %	6.1 %	90.2 %	93.8 %
Ceftazidime (204, 324)	>16	>16	>16	>16	6.4 %	5.8 %	93.6 %	94.1 %
Ceftazidime/avibactam (204, 324)	0.5	1	2	>16	94.1 %	87.9 %	5.8 %	12.0 %
Ceftolozane/tazobactam (204, 324)	>8	>16	>16	>16	18.1 %	20.3 %	81.8 %	79.6 %
Ceftriaxone (204, 324)	>8	>8	>8	>8	0.9 %	0.3 %	99.0 %	99.6 %
Ciprofloxacin (77, 0)	>2	–	>2	–	10.1 %	–	89.6 %	–
Colistin (204, 324)	≤1	≤1	>4	>4	81.9 %	75.3 %	18.1 %	24.6 %
Ertapenem (204, 324)	>4	>2	>4	>4	31.4 %	27.1 %	68.6 %	72.8 %
Imipenem (204, 324)	8	>16	>16	>16	47.5 %	33.3 %	52.4 %	66.6 %
Imipenem/relebactam (204, 324)	0.25	0.25	1	8	93.6 %	87.0 %	6.3 %	12.9 %
Meropenem (204, 324)	4	16	>16	>16	56.4 %	42.9 %	43.6 %	57.1 %
Piperacillin/tazobactam (204, 324)	>64	>64	>64	>64	8.8 %	9.8 %	91.1 %	90.1 %
<i>P. aeruginosa</i> non-susceptible to ceftazidime								
Amikacin (288, 405)	≤4	≤4	>32	32	87.8 %	89.3 %	12.1 %	10.6 %
Aztreonam (288, 405)	8	8	>16	>16	78.4 %	79.7 %	21.5 %	20.2 %
Cefepime (288, 405)	4	4	32	32	71.8 %	79.0 %	28.1 %	20.9 %
Ceftazidime (288, 405)	4	4	>32	>32	70.8 %	79.2 %	29.1 %	20.7 %
Ceftazidime/avibactam (288, 405)	2	2	16	8	87.5 %	90.3 %	12.5 %	9.6 %
Ceftolozane/tazobactam (288, 405)	0.5	0.5	8	4	88.8 %	92.8 %	11.1 %	7.1 %
Ciprofloxacin (136,0)	≤0.25	–	>2	–	61.7 %	–	38.2 %	–
Colistin (288, 405)	≤1	1	≤1	1	99.31 %	100.0 %	0.6 %	0.0 %
Imipenem (288, 405)	2	4	32	32	63.8 %	66.9 %	36.1 %	33.0 %
Imipenem/relebactam (288, 405)	1	1	4	4	80.9 %	81.2 %	19.1 %	18.7 %
Meropenem (288, 405)	1	1	32	16	76.3 %	82.7 %	23.6 %	17.2 %
Piperacillin/tazobactam (288, 405)	8	8	>64	> 64	65.2 %	73.5 %	34.7 %	26.4 %
<i>P. aeruginosa</i> non-susceptible to Meropenem								
Amikacin (100, 130)	≤4	8	>32	>32	76.0 %	73.8 %	24.0 %	26.1 %
Aztreonam (100, 130)	16	16	>16	>16	60.0 %	55.3 %	40.0 %	44.6 %
Cefepime (100, 130)	16	8	>32	>32	45.0 %	50.7 %	55.0 %	49.2 %
Ceftazidime (100, 130)	16	8	>32	>32	47.0 %	53.0 %	53.0 %	46.9 %
Ceftazidime/avibactam (100, 130)	8	4	>32	>32	70.0 %	73.8 %	30.0 %	26.1 %
Ceftolozane/tazobactam (100, 130)	1	1	>32	>32	73.0 %	78.4 %	27.0 %	21.5 %
Colistin (100, 130)	≤1	1	≤1	1	100.0 %	100.0 %	0.0 %	0.0 %
Imipenem (100, 130)	32	32	>32	>32	7.0 %	10.7 %	93.0 %	89.2 %
Imipenem/relebactam (100, 130)	4	4	>32	>32	46.0 %	43.0 %	54.0 %	56.9 %
Meropenem (100, 130)	16	16	>32	>32	32.0 %	46.1 %	68.0 %	53.8 %
Piperacillin/tazobactam (100, 130)	32	32	>64	>64	36.0 %	42.3 %	64.0 %	57.6 %

GNB, Gram-Negative Bacilli; N1, Number of isolates tested during 2018–2019; N2, Number of isolates tested during 2020–2021; EUCAST, European Committee on Antimicrobial Susceptibility Testing; SI +SIE, Susceptible + Susceptible Increased exposure.

systems might be one of the major non-enzymatic resistance mechanisms. However, it is worth noting that imipenem is not subject to efflux in *P. aeruginosa*. Based on the findings of numerous investigations, ceftolozane/tazobactam is a highly efficacious agent against *P. aeruginosa* isolates.^{39–42} One of the studies from Poland reported that 86.0 % of carbapenem-resistant *P. aeruginosa* were susceptible to ceftolozane/tazobactam.³⁹ Pfaller et al. conducted a study in 7 APAC countries and reported ceftolozane/tazobactam as the most potent against *P. aeruginosa* isolates with 90.8 % susceptibility.⁴⁰ Similar results were reported in our study, ceftolozane/tazobactam showed high susceptibility against *P. aeruginosa* isolates in 2018–2019 (88.8 %) and 2020–

2021 (92.8 %). It also demonstrated good susceptibility for *P. aeruginosa* isolates non-susceptible to ceftazidime and meropenem.

In this current study, *bla*_{KPC-2} gene was found in only six isolates of *P. aeruginosa*. This finding is consistent with earlier studies reporting a low prevalence of carbapenemase production.^{41,43,44} In the present study, *bla*_{KPC-2} was identified as the most prevalent carbapenemase encoding gene among *Enterobacteriales* species. Additionally, the presence of *bla*_{KPC-3} and *bla*_{KPC-30}, which have been infrequently reported in Brazil, was also observed. Surveillance studies thus help provide more understanding and opportunities to find better treatment options for resistant strains.

Table 3
Distribution of beta-lactamase encoding genes according to bacterial species.

Bacterial species/B-lactamase encoding genes	Number	Percentage
<i>E. coli</i>	250 ^a	–
Carbapenemases	17	–
<i>bla</i> _{KPC-2}	15	88.2
<i>bla</i> _{NDM-1}	2	11.8
ESBL	18	–
<i>bla</i> _{CTX-M-1-240G}	9	50.0
<i>bla</i> _{CTX-M-8-240D}	4	22.2
<i>bla</i> _{CMY-2-TYPE}	1	5.6
<i>bla</i> _{CTX-M-15}	1	5.6
<i>bla</i> _{CTX-M-2}	1	5.6
<i>bla</i> _{CTX-M-2-240D}	1	5.6
<i>bla</i> _{CTX-M-8}	1	5.6
<i>bla</i> _{CTX-M-9-240D}	1	5.6
<i>bla</i> _{CTX-M-9-240G}	1	5.6
<i>K. pneumoniae</i>	494 ^b	–
Carbapenemases	302	–
<i>bla</i> _{KPC-2}	260	86.1
<i>bla</i> _{NDM-1}	37	12.3
<i>bla</i> _{KPC-3}	7	2.3
<i>bla</i> _{NDM-7}	6	2.0
<i>bla</i> _{OXA-370}	3	1.0
<i>bla</i> _{KPC-30}	1	0.3
<i>bla</i> _{KPC-31}	1	0.3
<i>bla</i> _{NDM-5}	1	0.3
<i>bla</i> _{VIM-1}	1	0.3
ESBL	320	–
<i>bla</i> _{CTX-M-1-240G}	173	54.1
<i>bla</i> _{CTX-M-2-240D}	53	16.6
<i>bla</i> _{CTX-M-9-240D}	48	15.0
<i>bla</i> _{CTX-M-15}	33	10.3
<i>bla</i> _{CTX-M-14}	7	2.2
<i>bla</i> _{CTX-M-2}	4	1.3
<i>bla</i> _{CTX-M-8}	4	1.3
<i>bla</i> _{CTX-M-8-240D}	3	0.9
<i>bla</i> _{OXA-370}	3	0.9
<i>bla</i> _{SHV-ESBL}	3	0.9
<i>bla</i> _{CTX-M-9-TYPE}	2	0.6
<i>bla</i> _{CTX-M-1-240D}	1	0.3
<i>bla</i> _{CTX-M-9-240G}	1	0.3
<i>P. aeruginosa</i>	353 ^c	–
Carbapenemases	23	–
<i>bla</i> _{SPM-1}	10	43.5
<i>bla</i> _{VIM-2}	9	39.1
<i>bla</i> _{KPC-2}	6	26.1
<i>bla</i> _{IMP-56}	1	4.3
ESBL	9	–
<i>bla</i> _{CTX-M-2}	4	44.4
<i>bla</i> _{CTX-M-229}	4	44.4
<i>bla</i> _{GES-1}	1	11.1
Other mechanisms	22	95.7

^a 250 *E. coli* were tested.

^b 494 *K. pneumoniae* were tested.

^c 353 *P. aeruginosa* were tested.

The COVID-19 pandemic has resulted in a surge of hospitalizations and ICU admissions, leading to a significant escalation in antibiotic usage, which has further accelerated the spread of AMR. Consequently, it is imperative to conduct a comprehensive evaluation of AMR in the post-COVID-19 era. This is particularly crucial in Brazilian hospitals, where GNB infections are highly prevalent, and the exacerbation of the AMR problem during the pandemic has been observed.^{30,45,46} In the present study, we observed increased resistance (> 10 %) of many antibiotics for *K. pneumoniae* including imipenem (14.1 %), meropenem (12.9 %) and amikacin (10.2 %) before (2018–2019) and after pandemic (2020–2021). Consequently, it is imperative to focus on developing novel antibiotic therapies, preventing the excessive use of existing medications, and placing significant emphasis on surveillance studies to get a comprehensive understanding of the present situation.

Conclusion

This study demonstrates the favorable *in vitro* activity of ceftolozane/tazobactam against different GNB infections in Brazil. Our findings indicate that ceftolozane/tazobactam exhibits potent *in vitro* activity against *E. coli* and *P. aeruginosa* isolates. However, it is important to note that this antibiotic showed limited *in vitro* activity against *K. pneumoniae* in the Brazilian cohort, likely due to the widespread production of ESBL and *bla*_{KPC-2}. As new mechanisms of antibiotic resistance continue to emerge, especially with the rise of carbapenem resistance, it is crucial to assess the current landscape of antimicrobial resistance to identify optimal therapeutic approaches.

Ceftolozane/tazobactam demonstrates significant *in vitro* susceptibility against carbapenem-resistant *P. aeruginosa*, which positions it as an important treatment option. Further studies are warranted to enhance our understanding of the treatment options available for multidrug-resistant organisms causing infections and to prevent unfavourable outcomes in patients.

Funding

MSD Brazil, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, provided financial support for this study.

Conflicts of interest

Amanda Azevedo Bittencourt, Vinicius Lima Faustino, Paula de Mendonça Batista, Marina Della Negra de Paula and Thales José Polis are employees of MSD subsidiaries of Merck & Co., Inc., Rahway, NJ, USA. Lays Paulino Leonel is employee of IQVIA Brazil.

Acknowledgments

We would like to express our deep gratitude to the Brazilian participating medical study sites of the SMART Program for providing the bacterial isolates used in this study. We thank all for their valuable contributions to the program.

Additionally, we would like to acknowledge IHMA (International Health Management Associates, Schaumburg, IL, USA) for their assistance and contribution in conducting the necessary laboratory tests.

References

- Antimicrobial resistance: world Health Organization; 2021 [Available from: <https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance>.
- Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. *Lancet*. 2022;399:629–655.
- Costa-Júnior SD, Ferreira YLA, Agreles MAA, et al. Gram-negative bacilli carrying *mcr* gene in Brazil: a pathogen on the rise. *Braz J Microbiol*. 2023;54:1009–1020.
- de Carvalho Hessel Dias VM, Tuon F, de Jesus Capelo P, Telles JP, Fortaleza CMCB, Pellegrino Baena C. Trend analysis of carbapenem-resistant Gram-negative bacteria and antimicrobial consumption in the post-COVID-19 era: an extra challenge for healthcare institutions. *J Hospital Infect*. 2022;120:43–47.
- Furtado GHC, Martins ST, Machado AMO, Wey SB, Medeiros EAS. Clinical culture surveillance of carbapenem-resistant pseudomonas aeruginosa and acinetobacter species in a teaching hospital in São Paulo, Brazil: a 7-year study. *Infect Control Hospital Epidemiol*. 2006;27(11):1270–1273.
- Federico MP, Furtado GH. Immediate and later impacts of antimicrobial consumption on carbapenem-resistant Acinetobacter spp., Pseudomonas aeruginosa, and Klebsiella spp. in a teaching hospital in Brazil: a 10-year trend study. *Euro J Clin Microbiol Infect Dis*. 2018;37(11):2153–2158.
- Beirão EM, Rodrigues SDS, Andrade TK, et al. Activity of ceftolozane-tazobactam and comparators against gram-negative bacilli: results from the study for monitoring antimicrobial resistance trends (SMART - Brazil; 2016–2017). *Braz J Infect Dis*. 2020;24(4):310–321.
- Kiffer CRV, Rezende TFT, Costa-Nobre DT, Marinonio ASS, Shiguenaga LH, Kulek DNO, et al. A 7-Year Brazilian national perspective on plasmid-mediated carbapenem resistance in enterobacterales, pseudomonas aeruginosa, and acinetobacter baumannii complex and the impact of the coronavirus disease 2019 pandemic on their occurrence. *Clin Infect Dis*. 2023;77(Supplement_1):S29–S37.
- Polly M, de Almeida BL, Lennon RP, Cortes MF, Costa SF, Guimarães T. Impact of the COVID-19 pandemic on the incidence of multidrug-resistant bacterial infections in an acute care hospital in Brazil. *Am J Infect Control*. 2022;50(1):32–38.

10. Costa RLd, Lamas CdC, Simvoulidis LFN, Espanha CA, Moreira LPM, Bonancim RAB, et al. Secondary infections in a cohort of patients with COVID-19 admitted to an intensive care unit: impact of gram-negative bacterial resistance. *Rev Inst Med Trop Sao Paulo*. 2022;64:e6.
11. Gaspar GG, Ferreira LR, Feliciano CS, Campos Júnior CP, Molina FMR, Vendruscolo ACS, et al. Pre- and post-COVID-19 evaluation of antimicrobial susceptibility for healthcare-associated infections in the intensive care unit of a tertiary hospital. *Rev Soc Bras Med Trop*. 2021;54, e0902021.
12. Castro MG, Ubiergo L, Vicino M, Cuevas G, Argañá F. Rising incidence of carbapenem resistant isolates: an Argentinian hospital's experience. More trouble in the aftermath of the COVID-19 pandemic. *Iberoam J Med*. 2022;4(2):92–99.
13. Wilson APR. Sparing carbapenem usage. *J Antimicrob Chemother*. 2017;72: 2410–2417.
14. Han R, Sun D, Li S, Chen J, Teng M, Yang B, et al. Pharmacokinetic/ pharmacodynamic adequacy of novel β -lactam/ β -lactamase inhibitors against gram-negative bacterial in critically ill patients. *Antibiotics (Basel)*. 2021;10:993.
15. Wilson GM, Fitzpatrick M, Walding K, Gonzalez B, Schweizer ML, Suda KJ, et al. Meta-analysis of clinical outcomes using ceftazidime/avibactam, ceftolozane/tazobactam, and meropenem/vaborbactam for the treatment of multidrug-resistant gram-negative infections. *Open Forum Infect Dis*. 2021;8:ofaa651.
16. Karlowsky JA, Kazmierczak KM, Young K, Motyl MR, Sahn DF. *In vitro* activity of ceftolozane/tazobactam against phenotypically defined Extended-Spectrum β -Lactamase (ESBL)-positive isolates of *Escherichia coli* and *Klebsiella pneumoniae* isolated from hospitalized patients (SMART 2016). *Diagn Microbiol Infect Dis*. 2020; 96, 114925.
17. Cho JC, Fiorenza MA, Estrada SJ. Ceftolozane/tazobactam: a novel cephalosporin/ β -lactamase inhibitor combination. *Pharmacotherapy*. 2015;35:701–715.
18. López Montesinos I, Montero M, Sorlí L, Horcajada JP. Ceftolozane-tazobactam: when, how and why using it? *Rev Esp Quimioter*. 2021;34(Suppl 1):35–37. Suppl1.
19. Beirão EM, Rodrigues SdS, Andrade TKd, Serra FB, MDNd Paula, Polis TJB, et al. Activity of ceftolozane-tazobactam and comparators against gram-negative bacilli: results from the study for monitoring antimicrobial resistance trends (SMART – Brazil; 2016–2017). *Braz J Infect Dis*. 2020;24:310–321.
20. Gao W, Patel YT, Zhang Z, Johnson MG, Fiedler-Kelly J, Bruno CJ, et al. Ceftolozane/Tazobactam Probability of Target Attainment in Patients with Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia. *J Clin Pharmacol*. 2023;63: 352–357.
21. Martin-Loeches I, Shorr AF, Wunderink RG, Kollef MH, Timsit JF, Yu B, et al. Outcomes in participants with ventilated nosocomial pneumonia and organ failure treated with ceftolozane/tazobactam versus meropenem: a subset analysis of the phase 3, randomized, controlled ASPECT-NP trial. *Ann Intensive Care*. 2023;13:8.
22. Okuma A, Polis T, Pavia J, Mizuno G, Ferrari J, DeRyke CA. 624. Probability of target attainment of ceftolozane/tazobactam among adult patients with hospital-acquired pneumonia/ventilator-associated pneumonia secondary to pseudomonas aeruginosa in Latin America. *Open Forum Infect Dis*. 2022;9(Suppl 2). ofac492.676.
23. Lob SH, Kazmierczak KM, Chen WT, Siddiqui F, DeRyke CA, Young K, et al. *In vitro* activity of ceftolozane/tazobactam against Gram-negative isolates collected from ICU patients with lower respiratory tract infections in seven Asian countries – SMART 2017–2019. *J Glob Antimicrob Resist*. 2022;29:527–533.
24. *Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically – eleventh edition: M07*. Clinical & Laboratory Standards Institute; 2018 [Available from: https://clsi.org/media/1928/m07ed11_sample.pdf].
25. Estabrook M, Kazmierczak KM, Wise M, Arhin FF, Stone GG, Sahn DF. Molecular characterization of clinical isolates of Enterobacterales with elevated MIC values for aztreonam-avibactam from the INFORM global surveillance study, 2012-2017. *J Glob Antimicrob Resist*. 2021;24:316–320.
26. Bortolala V, Kaas RS, Ruppe E, Roberts MC, Schwarz S, Cattori V, et al. ResFinder 4.0 for predictions of phenotypes from genotypes. *J Antimicrob Chemother*. 2020;75: 3491–3500.
27. Fuhrmeister AS, Jones RN. The importance of antimicrobial resistance monitoring worldwide and the origins of SENTRY antimicrobial surveillance program. *Open Forum Infect Dis*. 2019;6(Suppl 1):S1–s4.
28. Sader HS, Rhomberg PR, Fuhrmeister AS, Mendes RE, Flamm RK, Jones RN. Antimicrobial resistance surveillance and new drug development. *Open Forum Infect Dis*. 2019;6(Supplement_1):S5–S13.
29. Pillonetto M, RTdS Jordão, Andraus GS, Bergamo R, Rocha FB, Onishi MC, et al. The experience of implementing a national antimicrobial resistance surveillance system in Brazil. *Front Public Health*. 2021;8, 575536.
30. Fuga B, Sella Fábio P, Cerdeira L, Esposito F, Cardoso B, Fontana H, et al. WHO critical priority *Escherichia coli* as one health challenge for a post-pandemic scenario: genomic surveillance and analysis of current Trends in Brazil. *Microbiol Spectr*. 2022;10. e01256-21.
31. García-Fernández S, García-Castillo M, Melo-Cristino J, Pinto MF, Gonçalves E, Alves V, et al. *In vitro* activity of ceftolozane-tazobactam against Enterobacterales and *Pseudomonas aeruginosa* causing urinary, intra-abdominal and lower respiratory tract infections in intensive care units in Portugal: the STEP multicenter study. *Int J Antimicrob Agents*. 2020;55, 105887.
32. Shorridge D, Carvalhaes CG, Streit JM, Flamm RK. Susceptibility trends of ceftolozane/tazobactam and comparators when tested against U.S. gram-negative bacterial surveillance isolates (2012–2018). *Diagn Microbiol Infect Dis*. 2021;100, 115302.
33. Sader HS, Carvalhaes CG, Duncan LR, Flamm RK, Shorridge D. Susceptibility trends of ceftolozane/tazobactam and comparators when tested against European Gram-negative bacterial surveillance isolates collected during 2012-18. *J Antimicrob Chemother*. 2020;75:2907–2913.
34. Paterson DL, Bassetti M, Motyl M, Johnson MG, Castanheira M, Jensen EH, et al. Ceftolozane/tazobactam for hospital-acquired/ventilator-associated bacterial pneumonia due to ESBL-producing Enterobacterales: a subgroup analysis of the ASPECT-NP clinical trial. *J Antimicrob Chemother*. 2022;77:2522–2531.
35. Bassetti M, Vena A, Giacobbe DR, Falcone M, Tiseo G, Giannella M, et al. Ceftolozane/Tazobactam for treatment of severe esbl-producing enterobacterales infections: a multicenter nationwide clinical experience (CEFTABUSE II Study). *Open Forum Infect Dis*. 2020;7:ofaa139.
36. Popejoy MW, Paterson DL, Cloutier D, Huntington JA, Miller B, Bliss CA, et al. Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing *Escherichia coli* and *Klebsiella pneumoniae*: a pooled analysis of Phase 3 clinical trials. *J Antimicrob Chemother*. 2017;72:268–272.
37. Pfaller MA, Shorridge D, Arends SJR, Duncan LR, Streit JM, Flamm RK. Activity of ceftolozane-tazobactam and comparators when tested against bacterial surveillance isolates collected from patients at risk of infections caused by resistant gram-negative pathogens. *Diagn Microbiol Infect Dis*. 2020;98, 115101.
38. Bahabri NM, Al-Alawi MM, Qutub MO, Tashkandi WA, Alturki R, Janah SS, et al. *In vitro* activity of ceftolozane/tazobactam against recent clinical bacterial isolates from two Saudi Arabian hospitals. *J Infect Public Health*. 2022;15:486–490.
39. Sękowska A, Grabowska M, Bogiel T. Satisfactory *In Vitro* Activity of Ceftolozane-Tazobactam against carbapenem-resistant *Pseudomonas aeruginosa* but not against *Klebsiella pneumoniae* isolates. *Medicina (Kaunas)*. 2023;59:518.
40. Pfaller MA, Shorridge D, Sader HS, Gales A, Castanheira M, Flamm RK. Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and *Pseudomonas aeruginosa* causing healthcare-associated infections in Latin America: report from an antimicrobial surveillance program (2013–2015). *Braz J Infect Dis*. 2017;21: 627–637.
41. JldC Lima, Ximenes RM, Maciel MAV. Occurrence of blaKPC gene in clinical isolates of *Pseudomonas aeruginosa* from Brazil. *ABCS Health Sci*. 2022;47, e022306.
42. Urzedo JE, de Paula, Menezes R, et al. High mortality by nosocomial infections caused by carbapenem-resistant *P. aeruginosa* in a referral hospital in Brazil: facing the perfect storm. *J Med Microbiol*. 2020;69:1388–1397.
43. de Paula-Petroli SB, Campana EH, Bocchi M, Bordinhão T, Picão RC, Yamada-Ogatta SF, et al. Early detection of a hypervirulent KPC-2-producing *Pseudomonas aeruginosa* ST235 in Brazil. *J Glob Antimicrob Resist*. 2018;12:153–154.
44. de Oliveira Santos IC, Albano RM, Asensi MD, D'Alincourt Carvalho-Assef AP. Draft genome sequence of KPC-2-producing *Pseudomonas aeruginosa* recovered from a bloodstream infection sample in Brazil. *J Glob Antimicrob Resist*. 2018;15:99–100.
45. Langford BJ, Soucy JPR, Leung V, So M, Kwan ATH, Portnoff JS, et al. Antibiotic resistance associated with the COVID-19 pandemic: a systematic review and meta-analysis. *Clin Microbiol Infect*. 2023;29:302–309.
46. Rossato L, Negrão FJ, Simionatto S. Could the COVID-19 pandemic aggravate antimicrobial resistance? *Am J Infect Control*. 2020;48:1129–1130.